HIGHLIGHTS
SUMMARY
This therapeutic hypothesis was clinically validated by the unprecedented clinical response rates of uveal melanoma cancer patients treated with a CD3 bispecific targeting the pHLA target gp100, known as T_cell receptor mimic (TCRm)-CD3 bispecific compounds. Two classes of T_cells harboring distinct effector mechanisms can be differentiated based on the expression of either CD4 (helper T_cells) or CD8 (killer T_cells) co-receptors. CD4+ T_cells recognize antigens in the context of MHC II and orchestrate the adaptive immune_response by secretion of cytokines with pro-inflammatory, chemotactic or immunosuppressive properties. CD8+ T_cells recognize antigens bound by . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.